Phase 1 Clinical Trial Begins for New CNS-Penetrant TYK2 Inhibitor

AI-generated NewsSnap summary based on source reporting.
Published: 2026-06-10
Category: health
Source: Plataforma Media (via PRNewswire)
Original source

Lynk Pharmaceuticals' partner, Formation Bio, has commenced a Phase 1 clinical trial for BLKR201 (LNK01006). This novel TYK2 inhibitor is designed to target immune signaling in the central nervous system, potentially addressing neural, autoimmune, and inflammatory conditions. Initial data from this trial in healthy volunteers are anticipated in early 2027.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai